Skip to main content
Signal8
Launch Terminal
Wadhane Jitendra profile photo

Jitendra Wadhane

CIK: 0001941706

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Pyxis Oncology, Inc. logo
PYXS

Pyxis Oncology, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Pyxis Oncology, Inc. logo
    PYXS

    Pyxis Oncology, Inc.

    Mar 24, 2026
    Award(A)
    Direct
    109.5K shares-
  • Pyxis Oncology, Inc. logo
    PYXS

    Pyxis Oncology, Inc.

    Mar 31, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    263.8K shares at avg. $0.98-
  • Pyxis Oncology, Inc. logo
    PYXS

    Pyxis Oncology, Inc.

    Dec 23, 2024
    Award(A)

    Stock Option (Right to Buy)

    Direct
    150K shares-

1-3 of 3

About Wadhane Jitendra

Wadhane Jitendra (SEC CIK 0001941706) files insider reports with the SEC as Prin Fin & Acct Officer of Pyxis Oncology, Inc. (PYXS).

Signal8 holds 3 ownership filings by Wadhane Jitendra, all Form 4s, filed between Dec 23, 2024 and Mar 25, 2026. Those filings report 3 transactions, from Dec 23, 2024 to Mar 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Wadhane Jitendra's filings is in BOSTON, MA.

Recent filings by Wadhane Jitendra

  • Mar 24, 2026: Grant or award of PYXS shares (Form 4, code A).
  • Mar 31, 2025: Grant or award of PYXS derivative securities (Form 4, code A).
  • Dec 23, 2024: Grant or award of PYXS derivative securities (Form 4, code A).

Other insiders filing for Pyxis Oncology, Inc. (PYXS)

How to read Form 4 transaction codes